Large shareholder sells some Orphazyme shares shortly before vital FDA ruling, general partner denies connection
Sunstone Life Science Ventures is not selling its Orphazyme shares because of the upcoming crucial FDA ruling, general partner Sten Verland tells MedWatch.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY CATHERINE BRETT
As the FDA's response deadline for Orphazyme's drug candidate arimoclomol draws ever closer, Sunstone Life Science Ventures has opted to sell some of its shares in the biotech company.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
